Lv6
2030 积分 2021-06-15 加入
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report
3天前
已完结
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
21天前
已完结
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash
1个月前
已完结
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
1个月前
已完结
Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
1个月前
已完结
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
1个月前
已完结
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
1个月前
已关闭
Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients
2个月前
已完结
ALK in cancer: from function to therapeutic targeting
3个月前
已完结
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
